companydata.dkcompanydata.dk

Y-mAbs Therapeutics A/S: Financial statements 2018

CVR: 37053678

Source: annual report 2018, Danish Business Authority

01/01/2018 – 31/12/2018

Y-mAbs Therapeutics A/S (CVR 37053678) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK 28,598,680 and a net result of DKK -4,193,681 compared with DKK -2,177,894 the year before. That is an increase of 116.8% compared with the year before. Equity in the 2018 report amounted to DKK 1,614,476. The solvency ratio was 9.4%. The company had 19 employees in the financial year.

Gross Profit
DKK 28,598,680
Profit/Loss
DKK -4,193,681
Equity
DKK 1,614,476
Total Assets
DKK 17,236,728
Employees
19

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2018-28.6M-4.2M1.6M19
2017-13.2M-2.2M808K-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2018

Gérard Ber joins the board of Y-mAbs Therapeutics A/SDec 18, 2018

As of December 18, 2018, Gérard Ber has joined the board of directors of Y-mAbs Therapeutics A/S.

Michael Joachim Buschle leaves the board of Y-mAbs Therapeutics A/SDec 18, 2018

As of December 18, 2018, Michael Joachim Buschle has left the board of directors of Y-mAbs Therapeutics A/S.

Y-mAbs Therapeutics A/S: The 2017 annual report is outMay 31, 2018

Y-mAbs Therapeutics A/S has published its annual report for 2017. Gross profit came to DKK 13,194,221, and the net result was DKK -2,177,894.

Ashutosh Tyagi joins the board of Y-mAbs Therapeutics A/SJan 18, 2018

As of January 18, 2018, Ashutosh Tyagi has joined the board of directors of Y-mAbs Therapeutics A/S.

David Neil Gill joins the board of Y-mAbs Therapeutics A/SJan 18, 2018

As of January 18, 2018, David Neil Gill has joined the board of directors of Y-mAbs Therapeutics A/S.

Michael Joachim Buschle joins the board of Y-mAbs Therapeutics A/SJan 18, 2018

As of January 18, 2018, Michael Joachim Buschle has joined the board of directors of Y-mAbs Therapeutics A/S.

Jim Irvin Healy joins the board of Y-mAbs Therapeutics A/SJan 18, 2018

As of January 18, 2018, Jim Irvin Healy has joined the board of directors of Y-mAbs Therapeutics A/S.

About Y-mAbs Therapeutics A/S

Y-mAbs Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Vincent Sainte-Catherine. The board consists of Antoine Bernasconi (chair), Julien Forest and Vincent Sainte-Catherine. The company is owned by Y-mAbs Therapeutics, Inc.. The company has 13 employees (2026). In 2025, the company reported a gross profit of DKK 29,300,371 and a net result of DKK -38,461,598 compared with DKK -12,500,464 the year before. Equity in the 2025 report amounted to DKK -163,651,844.

Source: annual report 2025, Danish Business Authority